Ozivy: Anvisa aprova novo medicamento à base de semaglutida

Em entrevista ao Show da Notícia, dr. Eduardo Salles, membro da Sociedade Brasileira Endocrinologia Metabologia, comenta a aprovação, pela Anvisa, de um novo medicamento à base de semaglutida no Brasil, o Ozivy. O especialista reforça que a versão aprovada no país é indicada, neste momento, para o tratamento do diabetes tipo 2, na dose de 1 mg. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published May 30, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ozivy: Anvisa aprova novo medicamento à base de semaglutida

0:00 14:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

BdF Entrevista Brasil de Fato Programa diário com entrevistas de 45 minutos sobre temas da atualidade. Vai ao ar na TVT e no YouTube, às 19h, e na Rádio Brasil de Fato (98.9 FM).

Frequently Asked Questions

How long is this episode of CBN Entrevistas?

This episode is 14 minutes long.

When was this CBN Entrevistas episode published?

This episode was published on May 30, 2026.

Can I download this CBN Entrevistas episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!